Enhanced Genomics

Enhanced Genomics is a biotechnology startup headquartered in United Kingdom, founded in 2020. The company's mission, encapsulated in the slogan "Transforming therapeutic development through functional genomics," underscores its commitment to advancing human healthcare. Enhanced Genomics is at the forefront of innovation in the field, offering a disruptive technology that profiles 3D genome folding at high resolution for all genes and their enhancers simultaneously. This approach allows the company to link gene enhancers and non-coding genetic variants to their target genes, thus unlocking their potential for therapeutic discovery.

Notably, Enhanced Genomics is a spinout company from the renowned Babraham Institute in Cambridge, UK. The company's strong foundations are underscored by its academic scientists, who are leaders in the fields of regulatory genomics and chromosomal architecture. Moreover, the recent £10.00M Series A investment on 20 October 2022 demonstrates the confidence of investors in Enhanced Genomics' potential. This milestone investment was led by Parkwalk Advisors, Bioqube Ventures, and the Business Growth Fund.

Overall, Enhanced Genomics stands out as a promising player in the biotechnology industry, poised to make significant contributions to therapeutic development and human health.